BusinessOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)By Nasdaq OMXApr 12, 2017, 8:08 PM UTC
BusinessOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)By Nasdaq OMXApr 12, 2017, 8:08 PM UTC
BusinessOcera to Present at the 16th Annual Needham Healthcare ConferenceBy Nasdaq OMXMar 27, 2017, 8:05 PM UTC
BusinessOcera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate UpdateBy Nasdaq OMXMar 10, 2017, 11:00 AM UTC
BusinessOcera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic EncephalopathyBy Nasdaq OMXMar 8, 2017, 1:05 PM UTC
BusinessOcera Announces Top-line Results for Phase 2b Study in Hepatic EncephalopathyBy Nasdaq OMXJan 30, 2017, 12:00 PM UTC
BusinessOcera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with CirrhosisBy Nasdaq OMXJan 5, 2017, 2:05 PM UTC
BusinessOcera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic EncephalopathyBy Nasdaq OMXDec 7, 2016, 2:05 PM UTC
